{"id":33040,"date":"2023-08-11T14:12:17","date_gmt":"2023-08-11T12:12:17","guid":{"rendered":"https:\/\/www.maiwald.eu\/?post_type=pressemitteilungen&#038;p=33040"},"modified":"2023-08-11T15:37:11","modified_gmt":"2023-08-11T13:37:11","slug":"another-win-for-maiwald-and-betapharm-arzneimittel-gmbh","status":"publish","type":"pressemitteilungen","link":"https:\/\/www.maiwald.eu\/cn\/pressemitteilungen\/another-win-for-maiwald-and-betapharm-arzneimittel-gmbh\/","title":{"rendered":"Another success for Maiwald and betapharm Arzneimittel GmbH"},"content":{"rendered":"\n<p>We are happy to report that the oppositions filed by our client betapharm and eight other generics manufacturers against Novartis patent EP 3 351 246 were successful; the Board of Appeal of the European Patent Office revoked the Novartis patent for lack of inventive step (file number: T0814\/22-3.3.07).<\/p>\n\n\n\n<p>In reaction to this decision, Novartis also withdrew its parallel infringement action against our client betapharm that was pending before the D\u00fcsseldorf Appeal Court.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-33040","pressemitteilungen","type-pressemitteilungen","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/pressemitteilungen\/33040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/pressemitteilungen"}],"about":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/types\/pressemitteilungen"}],"version-history":[{"count":2,"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/pressemitteilungen\/33040\/revisions"}],"predecessor-version":[{"id":33044,"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/pressemitteilungen\/33040\/revisions\/33044"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/media?parent=33040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}